IBT
ESPR icon

International Biotechnology Trust’s Esperion Therapeutics ESPR Stock Holding History

International Biotechnology Trust’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,500
Closed -$114K – 78
2021
Q3 		$114K Hold
9,500
– – 0.03% 68
2021
Q2 		$201K Hold
9,500
– – 0.05% 66
2021
Q1 		$266K Hold
9,500
– – 0.07% 55
2020
Q4 		$247K Hold
9,500
– – 0.07% 50
2020
Q3 		$353K Hold
9,500
– – 0.11% 51
2020
Q2 		$452K Hold
9,500
– – 0.15% 51
2020
Q1 		$298K Sell
9,500
-20,500
-68% -$1.08M 0.14% 54
2019
Q4 		$1.79M Buy
+30,000
New +$1.35M 0.64% 36
2018
Q2 		– Sell
-10,000
Closed -$723K – 58
2018
Q1 		$723K Buy
+10,000
New +$734K 0.28% 60

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

International Biotechnology Trust's ESPR Position: Q4 2021 in Review

International Biotechnology Trust sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 9,500 shares — an estimated $114K sold.

International Biotechnology Trust first reported a position in ESPR in Q1 2018 and held it in 9 quarters. The position peaked at $1.79M in Q4 2019. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • International Biotechnology Trust reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • International Biotechnology Trust sold 9,500 Esperion Therapeutics shares in Q4 2021, an estimated $114K.
  • International Biotechnology Trust first reported a position in Esperion Therapeutics in Q1 2018 and held it in 9 quarters.
  • International Biotechnology Trust's Esperion Therapeutics position peaked at $1.79M in Q4 2019.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on International Biotechnology Trust's 13F filing for Q4 2021, filed 15 Feb 2022.